These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37752798)

  • 1. Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation.
    Marrone G; Giannelli V; Agnes S; Avolio AW; Baiocchi L; Berardi G; Ettorre GM; Ferri F; Corradini SG; Grieco A; Guglielmo N; Lenci I; Lionetti R; Mennini G; Milana M; Rossi M; Spoletini G; Tisone G; Manzia TM; Lai Q
    Liver Int; 2024 Jan; 44(1):103-112. PubMed ID: 37752798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study.
    Rodríguez-Perálvarez ML; Gómez-Orellana AM; Majumdar A; Bailey M; McCaughan GW; Gow P; Guerrero M; Taylor R; Guijo-Rubio D; Hervás-Martínez C; Tsochatzis EA
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):242-252. PubMed ID: 36528041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposing a Sex-Adjusted Sodium-Adjusted MELD Score for Liver Transplant Allocation.
    Sealock JM; Ziogas IA; Zhao Z; Ye F; Alexopoulos SP; Matsuoka L; Chen G; Davis LK
    JAMA Surg; 2022 Jul; 157(7):618-626. PubMed ID: 35583884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study.
    Rodríguez-Perálvarez ML; de la Rosa G; Gómez-Orellana AM; Aguilera MV; Pascual Vicente T; Pereira S; Ortiz ML; Pagano G; Suarez F; González Grande R; Cachero A; Tomé S; Barreales M; Martín Mateos R; Pascual S; Romero M; Bilbao I; Alonso Martín C; Otón E; González Diéguez L; Espinosa MD; Arias Milla A; Blanco Fernández G; Lorente S; Cuadrado Lavín A; Redín García A; Sánchez Cano C; Cepeda-Franco C; Pons JA; Colmenero J; Guijo-Rubio D; Otero A; Amador Navarrete A; Romero Moreno S; Rodríguez Soler M; Hervás Martínez C; Gastaca M
    EClinicalMedicine; 2024 Aug; 74():102737. PubMed ID: 39114271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation.
    Lai Q; Magistri P; Lionetti R; Avolio AW; Lenci I; Giannelli V; Pecchi A; Ferri F; Marrone G; Angelico M; Milana M; Schinniná V; Menozzi R; Di Martino M; Grieco A; Manzia TM; Tisone G; Agnes S; Rossi M; Di Benedetto F; Ettorre GM;
    Liver Int; 2021 Jul; 41(7):1629-1640. PubMed ID: 33793054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.
    Kim WR; Mannalithara A; Heimbach JK; Kamath PS; Asrani SK; Biggins SW; Wood NL; Gentry SE; Kwong AJ
    Gastroenterology; 2021 Dec; 161(6):1887-1895.e4. PubMed ID: 34481845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of MELD3.0 in 2 centers from different continents.
    Tejedor M; Bellón JM; Fernández de la Varga M; Peralta P; Montalvá E; Selzner N; Berenguer M
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39082971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Model for End-stage Liver Disease accurately predicts 90-day liver transplant wait-list mortality in Atlantic Canada.
    Renfrew PD; Quan H; Doig CJ; Dixon E; Molinari M
    Can J Gastroenterol; 2011 Jul; 25(7):359-64. PubMed ID: 21876856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome.
    Goudsmit BFJ; Braat AE; Tushuizen ME; Vogelaar S; Pirenne J; Alwayn IPJ; van Hoek B; Putter H
    Am J Transplant; 2021 Nov; 21(11):3583-3592. PubMed ID: 34174149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Disparity in Liver Transplant and Access to Living Donation.
    Karnam RS; Chen S; Xu W; Chen C; Elangainesan P; Ghanekar A; McGilvray I; Reichman T; Sayed B; Selzner M; Sapisochin G; Galvin Z; Hirschfield G; Asrani SK; Selzner N; Cattral M; Lilly L; Bhat M
    JAMA Surg; 2021 Nov; 156(11):1010-1017. PubMed ID: 34406347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list.
    Myers RP; Shaheen AA; Faris P; Aspinall AI; Burak KW
    PLoS One; 2013; 8(1):e51926. PubMed ID: 23349678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.
    Goudsmit BFJ; Putter H; Tushuizen ME; de Boer J; Vogelaar S; Alwayn IPJ; van Hoek B; Braat AE
    Am J Transplant; 2021 Jan; 21(1):229-240. PubMed ID: 32529758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18.
    Biselli M; Dall'Agata M; Gramenzi A; Gitto S; Liberati C; Brodosi L; Ravaioli M; Gambato M; Montalti R; Pinna AD; Burra P; Gerunda GE; Cillo U; Andreone P; Bernardi M
    Liver Int; 2015 Jan; 35(1):184-91. PubMed ID: 24650058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Lai JC; Covinsky KE; Dodge JL; Boscardin WJ; Segev DL; Roberts JP; Feng S
    Hepatology; 2017 Aug; 66(2):564-574. PubMed ID: 28422306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical epidemiological analysis of the mortality rate of liver transplant candidates living in rural areas.
    Molinari M; Renfrew PD; Petrie NM; De Coutere S; Abdolell M
    Transpl Int; 2011 Mar; 24(3):292-9. PubMed ID: 21143650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure.
    Hernaez R; Liu Y; Kramer JR; Rana A; El-Serag HB; Kanwal F
    J Hepatol; 2020 Dec; 73(6):1425-1433. PubMed ID: 32531416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?
    Tejedor M; Selzner N; Berenguer M
    Transplantation; 2022 Nov; 106(11):2122-2136. PubMed ID: 35594480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate.
    Myers RP; Shaheen AA; Aspinall AI; Quinn RR; Burak KW
    J Hepatol; 2011 Mar; 54(3):462-70. PubMed ID: 21109324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of MELD-Na versus MELDNa in the prediction of short-term prognosis for acute-on-chronic hepatitis B liver failure].
    He WP; Hu JH; Tong JJ; Liu FF; Wang HF
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(17):1173-7. PubMed ID: 21756769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
    J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.